Protalix BioTherapeutics, Inc. (PLX) 10-Year Financial Performance & Capital Metrics

PLX • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutProtalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.Show more

Revenue $53M -18.5%
EBITDA $5M -55.2%
Net Income $3M -64.7%
EPS (Diluted) 0.04 -63.4%
Gross Margin 54.46% -16.1%
EBITDA Margin 9.78% -45.0%
Operating Margin 7.34% -54.1%
Net Margin 5.49% -56.7%
ROE 7.64% -89.5%
ROIC 8.82% -75.6%
Debt/Equity 0.13 -84.5%
Interest Coverage 3.69 +12.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 40.1%
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y13.42%

5Y-0.48%

3Y11.67%

TTM35.42%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM156.15%

EPS CAGR

10Y-

5Y-

3Y-

TTM150.61%

ROCE

10Y Avg-54.09%

5Y Avg-46.15%

3Y Avg0.62%

Latest9.04%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.36M	9.2M	21.08M	34.24M	54.69M	62.9M	38.35M	47.64M	65.49M	53.4M
Revenue Growth %	-0.71%	1.11%	1.29%	0.62%	0.6%	0.15%	-0.39%	0.24%	0.37%	-0.18%
Cost of Goods Sold+	730K	8.4M	15.23M	9.3M	10.89M	10.87M	16.35M	19.59M	22.98M	24.32M
COGS % of Revenue	0.17%	0.91%	0.72%	0.27%	0.2%	0.17%	0.43%	0.41%	0.35%	0.46%
Gross Profit+	3.63M	801K	5.85M	24.94M	43.8M	52.02M	22M	28.05M	42.51M	29.08M
Gross Margin %	0.83%	0.09%	0.28%	0.73%	0.8%	0.83%	0.57%	0.59%	0.65%	0.54%
Gross Profit Growth %	-0.4%	-0.78%	6.3%	3.27%	0.76%	0.19%	-0.58%	0.27%	0.52%	-0.32%
Operating Expenses+	27.3M	33.96M	40.36M	44.25M	54.52M	49.31M	42.46M	41.06M	32.05M	25.16M
OpEx % of Revenue	6.26%	3.69%	1.91%	1.29%	1%	0.78%	1.11%	0.86%	0.49%	0.47%
Selling, General & Admin	7.28M	9.36M	11.53M	10.92M	9.9M	11.15M	12.73M	11.71M	14.96M	12.19M
SG&A % of Revenue	1.67%	1.02%	0.55%	0.32%	0.18%	0.18%	0.33%	0.25%	0.23%	0.23%
Research & Development	20.02M	30.41M	28.83M	33.33M	44.62M	38.17M	29.73M	29.35M	17.09M	12.97M
R&D % of Revenue	4.59%	3.31%	1.37%	0.97%	0.82%	0.61%	0.78%	0.62%	0.26%	0.24%
Other Operating Expenses	0	-6.8M	0	0	0	0	0	0	0	0
Operating Income+	-23.67M	-33.16M	-34.52M	-19.31M	-10.72M	2.71M	-20.46M	-13.01M	10.46M	3.92M
Operating Margin %	-5.42%	-3.61%	-1.64%	-0.56%	-0.2%	0.04%	-0.53%	-0.27%	0.16%	0.07%
Operating Income Growth %	0.17%	-0.4%	-0.04%	0.44%	0.44%	1.25%	-8.55%	0.36%	1.8%	-0.63%
EBITDA+	-21.3M	-31.18M	-32.6M	-17.64M	-9.1M	4.01M	-19.34M	-11.93M	11.65M	5.22M
EBITDA Margin %	-4.88%	-3.39%	-1.55%	-0.52%	-0.17%	0.06%	-0.5%	-0.25%	0.18%	0.1%
EBITDA Growth %	0.16%	-0.46%	-0.05%	0.46%	0.48%	1.44%	-5.82%	0.38%	1.98%	-0.55%
D&A (Non-Cash Add-back)	2.37M	1.98M	1.92M	1.67M	1.62M	1.3M	1.12M	1.09M	1.19M	1.3M
EBIT	-23.55M	-24.98M	-73.72M	-18.77M	-10.31M	3.15M	-20.06M	-11.87M	11.75M	5.22M
Net Interest Income+	-3.61M	-3.6M	-9.54M	-7.15M	-7.56M	-9.23M	-7.12M	-1.38M	-1.89M	237K
Interest Income	123K	589K	188K	536K	407K	438K	401K	1.15M	1.29M	1.3M
Interest Expense	3.73M	4.19M	9.72M	7.68M	7.97M	9.67M	7.52M	2.53M	3.18M	1.06M
Other Income/Expense	-3.61M	3.99M	-48.92M	-7.15M	-7.56M	-9.23M	-7.12M	-1.38M	-1.89M	237K
Pretax Income+	-27.28M	-29.18M	-83.44M	-26.46M	-18.28M	-6.52M	-27.58M	-14.4M	8.57M	4.15M
Pretax Margin %	-6.25%	-3.17%	-3.96%	-0.77%	-0.33%	-0.1%	-0.72%	-0.3%	0.13%	0.08%
Income Tax+	0	0	0	0	0	0	0	530K	254K	1.22M
Effective Tax Rate %	-2.13%	1.01%	1%	1%	1%	1%	1%	1.04%	0.97%	0.71%
Net Income+	58.04M	-29.36M	-83.44M	-26.46M	-18.28M	-6.52M	-27.58M	-14.93M	8.31M	2.93M
Net Margin %	13.3%	-3.19%	-3.96%	-0.77%	-0.33%	-0.1%	-0.72%	-0.31%	0.13%	0.05%
Net Income Growth %	2.94%	-1.51%	-1.84%	0.68%	0.31%	0.64%	-3.23%	0.46%	1.56%	-0.65%
Net Income (Continuing)	-27.28M	-29.18M	-83.44M	-26.46M	-18.28M	-6.52M	-27.58M	-14.93M	8.31M	2.93M
Discontinued Operations	85.32M	-189K	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.61	-0.29	-6.50	-1.80	-1.23	-0.22	-0.62	-0.31	0.10	0.04
EPS Growth %	2.91%	-1.48%	-21.41%	0.72%	0.32%	0.82%	-1.82%	0.5%	1.32%	-0.63%
EPS (Basic)	0.61	-0.29	-6.50	-1.80	-1.23	-0.22	-0.62	-0.31	0.12	0.04
Diluted Shares Outstanding	94.92M	101.39M	13.11M	14.71M	14.84M	29.15M	44.14M	48.47M	82.42M	81.06M
Basic Shares Outstanding	94.92M	101.39M	13.11M	14.71M	14.84M	29.15M	44.14M	48.47M	67.51M	72.53M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	85.88M	71.87M	62.65M	52.98M	32.48M	55.72M	61.67M	44.88M	69.93M	60.08M
Cash & Short-Term Investments	76.37M	63.28M	51.16M	37.81M	17.79M	38.55M	38.98M	22.18M	44.56M	34.83M
Cash Only	76.37M	63.28M	51.16M	37.81M	17.79M	18.27M	38.98M	17.11M	23.63M	19.76M
Short-Term Investments	0	0	0	0	0	20.28M	0	5.07M	20.93M	15.07M
Accounts Receivable	0	693K	1.72M	4.73M	4.7M	2M	3.44M	4.59M	5.27M	2.91M
Days Sales Outstanding	-	27.5	29.8	50.41	31.37	11.61	32.76	35.14	29.38	19.88
Inventory	5.77M	5.25M	7.83M	8.57M	8.15M	13.08M	17.95M	16.8M	19.05M	21.24M
Days Inventory Outstanding	2.88K	227.96	187.71	336.24	273.21	439.15	400.83	313.06	302.47	318.83
Other Current Assets	3.33M	2.23M	1.5M	1.42M	1.52M	1.25M	380K	536K	611K	596K
Total Non-Current Assets+	11.37M	10.38M	9.56M	8.15M	12.91M	12.21M	12M	10.91M	14.5M	13.34M
Property, Plant & Equipment	9.74M	8.7M	7.68M	6.39M	10.95M	10.41M	9.92M	9.64M	10.88M	10.02M
Fixed Asset Turnover	0.45x	1.06x	2.75x	5.36x	4.99x	6.04x	3.87x	4.94x	6.02x	5.33x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	1.63M	1.68M	1.89M	1.76M	1.96M	1.8M	2.08M	1.27M	528K	462K
Total Assets+	97.25M	82.25M	72.21M	61.13M	45.39M	67.93M	73.67M	55.79M	84.43M	73.42M
Asset Turnover	0.04x	0.11x	0.29x	0.56x	1.20x	0.93x	0.52x	0.85x	0.78x	0.73x
Asset Growth %	0.24%	-0.15%	-0.12%	-0.15%	-0.26%	0.5%	0.08%	-0.24%	0.51%	-0.13%
Total Current Liabilities+	11.23M	66.21M	22.75M	25.35M	40.17M	86.47M	33.18M	32.43M	45.53M	25.62M
Accounts Payable	3.63M	4.01M	7.52M	5.21M	6.5M	7.22M	6.99M	5.86M	4.32M	4.53M
Days Payables Outstanding	1.81K	174.16	180.24	204.47	217.59	242.4	155.97	109.21	68.61	68.04
Short-Term Debt	0	53.87M	5.92M	0	4.3M	58.51M	0	0	21.66M	0
Deferred Revenue (Current)	504K	837K	1000K	1000K	1000K	1000K	1000K	1000K	0	0
Other Current Liabilities	5.98M	1.4M	526K	9.18M	1.75M	1.53M	1.51M	11.05M	4.94M	1.81M
Current Ratio	7.64x	1.09x	2.75x	2.09x	0.81x	0.64x	1.86x	1.38x	1.54x	2.34x
Quick Ratio	7.13x	1.01x	2.41x	1.75x	0.61x	0.49x	1.32x	0.87x	1.12x	1.52x
Cash Conversion Cycle	-	81.3	37.28	182.18	86.98	208.36	277.63	238.99	263.24	270.68
Total Non-Current Liabilities+	75.14M	25.99M	80.75M	88.66M	75.54M	8.5M	46.52M	34M	5.33M	4.58M
Long-Term Debt	72.1M	23.64M	46.27M	47.97M	50.96M	0	27.89M	28.19M	0	0
Capital Lease Obligations	0	0	0	0	4.53M	4.47M	4.38M	4.17M	4.62M	4.03M
Deferred Tax Liabilities	0	0	2.59M	2.37M	0	0	0	0	0	0
Other Non-Current Liabilities	2.3M	2.35M	7.64M	7.67M	3.07M	2.31M	2.47M	1.64M	714K	559K
Total Liabilities	86.38M	92.2M	103.51M	114.01M	115.71M	94.97M	79.7M	66.43M	50.87M	30.21M
Total Debt+	72.1M	77.52M	52.19M	47.97M	60.92M	64.4M	33.47M	33.47M	27.69M	5.53M
Net Debt	-4.28M	14.23M	1.02M	10.16M	43.13M	46.13M	-5.51M	16.36M	4.06M	-14.23M
Debt / Equity	6.63x	-	-	-	-	-	-	-	0.82x	0.13x
Debt / EBITDA	-	-	-	-	-	16.05x	-	-	2.38x	1.06x
Net Debt / EBITDA	-	-	-	-	-	11.50x	-	-	0.35x	-2.73x
Interest Coverage	-6.34x	-7.91x	-3.55x	-2.51x	-1.35x	0.28x	-2.72x	-5.15x	3.29x	3.69x
Total Equity+	10.87M	-9.96M	-31.29M	-52.88M	-70.32M	-27.04M	-6.04M	-10.64M	33.57M	43.21M
Equity Growth %	1.2%	-1.92%	-2.14%	-0.69%	-0.33%	0.62%	0.78%	-0.76%	4.15%	0.29%
Book Value per Share	0.11	-0.10	-2.39	-3.59	-4.74	-0.93	-0.14	-0.22	0.41	0.53
Total Shareholders' Equity	10.87M	-9.96M	-31.29M	-52.88M	-70.32M	-27.04M	-6.04M	-10.64M	33.57M	43.21M
Common Stock	100K	124K	144K	148K	15K	35K	46K	54K	73K	76K
Retained Earnings	-183.29M	-212.66M	-297.93M	-322.55M	-340.83M	-347.35M	-374.93M	-389.86M	-381.55M	-378.39M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-183.29M	-25.6M	-27.46M	-29.12M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-24.28M	-32.1M	-9.99M	-7.74M	-19.36M	-26.11M	-10.29M	-25M	-1.32M	8.67M
Operating CF Margin %	-5.56%	-3.49%	-0.47%	-0.23%	-0.35%	-0.42%	-0.27%	-0.52%	-0.02%	0.16%
Operating CF Growth %	0.17%	-0.32%	0.69%	0.23%	-1.5%	-0.35%	0.61%	-1.43%	0.95%	7.58%
Net Income	-27.28M	-29.18M	-85.28M	-26.46M	-18.28M	-6.52M	-27.58M	-14.93M	8.31M	2.93M
Depreciation & Amortization	2.37M	1.98M	1.92M	1.67M	1.62M	1.3M	1.12M	1.09M	1.19M	1.3M
Stock-Based Compensation	1.8M	988K	337K	514K	835K	3.13M	2.38M	2.08M	3.45M	3.25M
Deferred Taxes	1.56M	-7.59M	39.35M	-64K	-68K	0	0	0	-3.09M	236K
Other Non-Cash Items	569K	581K	4.57M	3.07M	3.37M	3.12M	3.9M	-1.23M	-638K	138K
Working Capital Changes	-3.3M	1.12M	29.1M	13.53M	-6.83M	-27.13M	9.9M	-12.02M	-10.54M	811K
Change in Receivables	523K	-1.13M	25K	-3.1M	188K	2.09M	-1.03M	-1.19M	-428K	2.32M
Change in Inventory	-2.32M	522K	-2.59M	-736K	414K	-4.93M	-4.87M	1.15M	-2.24M	-2.2M
Change in Payables	-1.87M	2.14M	4.9M	-520K	2.14M	0	0	0	0	0
Cash from Investing+	39.39M	-967K	-1.12M	-591K	-883K	-19.95M	18.92M	-5.04M	-16.71M	4.22M
Capital Expenditures	-464K	-849K	-971K	-686K	-627K	-655K	-1.46M	-628K	-1.15M	-1.28M
CapEx % of Revenue	0.11%	0.09%	0.05%	0.02%	0.01%	0.01%	0.04%	0.01%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	39.85M	-118K	-148K	95K	-256K	703K	380K	593K	-142K	83K
Cash from Financing+	6.63M	19.7M	-1.42M	-4.75M	0	46.47M	12.08M	8.24M	24.67M	-16.79M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	534K	14K	0	0	0	472K	0	2K	712K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-24.75M	-32.95M	-10.96M	-8.43M	-19.98M	-26.76M	-11.74M	-25.63M	-2.47M	7.39M
FCF Margin %	-5.67%	-3.58%	-0.52%	-0.25%	-0.37%	-0.43%	-0.31%	-0.54%	-0.04%	0.14%
FCF Growth %	0.18%	-0.33%	0.67%	0.23%	-1.37%	-0.34%	0.56%	-1.18%	0.9%	4%
FCF per Share	-0.26	-0.32	-0.84	-0.57	-1.35	-0.92	-0.27	-0.53	-0.03	0.09
FCF Conversion (FCF/Net Income)	-0.42x	1.09x	0.12x	0.29x	1.06x	4.00x	0.37x	1.67x	-0.16x	2.96x
Interest Paid	0	0	0	0	0	4.34M	3.41M	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	533.77%	-6411.57%	-	-	-	-	-	-	72.5%	7.64%
Return on Invested Capital (ROIC)	-	-457.46%	-	-	-	-	-406.69%	-170.55%	36.2%	8.82%
Gross Margin	83.27%	8.71%	27.74%	72.83%	80.08%	82.71%	57.37%	58.87%	64.91%	54.46%
Net Margin	1329.9%	-319.22%	-395.86%	-77.27%	-33.42%	-10.37%	-71.92%	-31.33%	12.69%	5.49%
Debt / Equity	6.63x	-	-	-	-	-	-	-	0.82x	0.13x
Interest Coverage	-6.34x	-7.91x	-3.55x	-2.51x	-1.35x	0.28x	-2.72x	-5.15x	3.29x	3.69x
FCF Conversion	-0.42x	1.09x	0.12x	0.29x	1.06x	4.00x	0.37x	1.67x	-0.16x	2.96x
Revenue Growth	-71.21%	110.79%	129.13%	62.44%	59.73%	15%	-39.03%	24.22%	37.48%	-18.47%

Revenue by Segment

	2018	2019	2021	2022	2023	2024
Product	5.32M	15.87M	-	-	-	52.98M
Product Growth	-	198.23%	-	-	-	-
License and Service	25.26M	-	-	-	-	418K
License and Service Growth	-	-	-	-	-	-
License and R&D Services	-	-	21.6M	22.35M	25.08M	-
License and R&D Services Growth	-	-	-	3.45%	12.22%	-
License And Service	-	38.83M	-	-	-	-
License And Service Growth	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Protalix BioTherapeutics, Inc. (PLX) has a price-to-earnings (P/E) ratio of 56.3x. This suggests investors expect higher future growth.

Growth & Financials

Protalix BioTherapeutics, Inc. (PLX) reported $61.8M in revenue for fiscal year 2024. This represents a 637% increase from $8.4M in 2011.

Protalix BioTherapeutics, Inc. (PLX) saw revenue decline by 18.5% over the past year.

Yes, Protalix BioTherapeutics, Inc. (PLX) is profitable, generating $5.4M in net income for fiscal year 2024 (5.5% net margin).

Dividend & Returns

Protalix BioTherapeutics, Inc. (PLX) has a return on equity (ROE) of 7.6%. This is below average, suggesting room for improvement.

Protalix BioTherapeutics, Inc. (PLX) had negative free cash flow of $11.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Protalix BioTherapeutics, Inc. (PLX) 10-Year Financial Performance & Capital Metrics

PLX • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $53M -18.5%
EBITDA $5M -55.2%
Net Income $3M -64.7%
EPS (Diluted) 0.04 -63.4%
Gross Margin 54.46% -16.1%
EBITDA Margin 9.78% -45.0%
Operating Margin 7.34% -54.1%
Net Margin 5.49% -56.7%
ROE 7.64% -89.5%
ROIC 8.82% -75.6%
Debt/Equity 0.13 -84.5%
Interest Coverage 3.69 +12.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 40.1%
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y13.42%

5Y-0.48%

3Y11.67%

TTM35.42%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM156.15%

EPS CAGR

10Y-

5Y-

3Y-

TTM150.61%

ROCE

10Y Avg-54.09%

5Y Avg-46.15%

3Y Avg0.62%

Latest9.04%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.36M	9.2M	21.08M	34.24M	54.69M	62.9M	38.35M	47.64M	65.49M	53.4M
Revenue Growth %	-0.71%	1.11%	1.29%	0.62%	0.6%	0.15%	-0.39%	0.24%	0.37%	-0.18%
Cost of Goods Sold+	730K	8.4M	15.23M	9.3M	10.89M	10.87M	16.35M	19.59M	22.98M	24.32M
COGS % of Revenue	0.17%	0.91%	0.72%	0.27%	0.2%	0.17%	0.43%	0.41%	0.35%	0.46%
Gross Profit+	3.63M	801K	5.85M	24.94M	43.8M	52.02M	22M	28.05M	42.51M	29.08M
Gross Margin %	0.83%	0.09%	0.28%	0.73%	0.8%	0.83%	0.57%	0.59%	0.65%	0.54%
Gross Profit Growth %	-0.4%	-0.78%	6.3%	3.27%	0.76%	0.19%	-0.58%	0.27%	0.52%	-0.32%
Operating Expenses+	27.3M	33.96M	40.36M	44.25M	54.52M	49.31M	42.46M	41.06M	32.05M	25.16M
OpEx % of Revenue	6.26%	3.69%	1.91%	1.29%	1%	0.78%	1.11%	0.86%	0.49%	0.47%
Selling, General & Admin	7.28M	9.36M	11.53M	10.92M	9.9M	11.15M	12.73M	11.71M	14.96M	12.19M
SG&A % of Revenue	1.67%	1.02%	0.55%	0.32%	0.18%	0.18%	0.33%	0.25%	0.23%	0.23%
Research & Development	20.02M	30.41M	28.83M	33.33M	44.62M	38.17M	29.73M	29.35M	17.09M	12.97M
R&D % of Revenue	4.59%	3.31%	1.37%	0.97%	0.82%	0.61%	0.78%	0.62%	0.26%	0.24%
Other Operating Expenses	0	-6.8M	0	0	0	0	0	0	0	0
Operating Income+	-23.67M	-33.16M	-34.52M	-19.31M	-10.72M	2.71M	-20.46M	-13.01M	10.46M	3.92M
Operating Margin %	-5.42%	-3.61%	-1.64%	-0.56%	-0.2%	0.04%	-0.53%	-0.27%	0.16%	0.07%
Operating Income Growth %	0.17%	-0.4%	-0.04%	0.44%	0.44%	1.25%	-8.55%	0.36%	1.8%	-0.63%
EBITDA+	-21.3M	-31.18M	-32.6M	-17.64M	-9.1M	4.01M	-19.34M	-11.93M	11.65M	5.22M
EBITDA Margin %	-4.88%	-3.39%	-1.55%	-0.52%	-0.17%	0.06%	-0.5%	-0.25%	0.18%	0.1%
EBITDA Growth %	0.16%	-0.46%	-0.05%	0.46%	0.48%	1.44%	-5.82%	0.38%	1.98%	-0.55%
D&A (Non-Cash Add-back)	2.37M	1.98M	1.92M	1.67M	1.62M	1.3M	1.12M	1.09M	1.19M	1.3M
EBIT	-23.55M	-24.98M	-73.72M	-18.77M	-10.31M	3.15M	-20.06M	-11.87M	11.75M	5.22M
Net Interest Income+	-3.61M	-3.6M	-9.54M	-7.15M	-7.56M	-9.23M	-7.12M	-1.38M	-1.89M	237K
Interest Income	123K	589K	188K	536K	407K	438K	401K	1.15M	1.29M	1.3M
Interest Expense	3.73M	4.19M	9.72M	7.68M	7.97M	9.67M	7.52M	2.53M	3.18M	1.06M
Other Income/Expense	-3.61M	3.99M	-48.92M	-7.15M	-7.56M	-9.23M	-7.12M	-1.38M	-1.89M	237K
Pretax Income+	-27.28M	-29.18M	-83.44M	-26.46M	-18.28M	-6.52M	-27.58M	-14.4M	8.57M	4.15M
Pretax Margin %	-6.25%	-3.17%	-3.96%	-0.77%	-0.33%	-0.1%	-0.72%	-0.3%	0.13%	0.08%
Income Tax+	0	0	0	0	0	0	0	530K	254K	1.22M
Effective Tax Rate %	-2.13%	1.01%	1%	1%	1%	1%	1%	1.04%	0.97%	0.71%
Net Income+	58.04M	-29.36M	-83.44M	-26.46M	-18.28M	-6.52M	-27.58M	-14.93M	8.31M	2.93M
Net Margin %	13.3%	-3.19%	-3.96%	-0.77%	-0.33%	-0.1%	-0.72%	-0.31%	0.13%	0.05%
Net Income Growth %	2.94%	-1.51%	-1.84%	0.68%	0.31%	0.64%	-3.23%	0.46%	1.56%	-0.65%
Net Income (Continuing)	-27.28M	-29.18M	-83.44M	-26.46M	-18.28M	-6.52M	-27.58M	-14.93M	8.31M	2.93M
Discontinued Operations	85.32M	-189K	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.61	-0.29	-6.50	-1.80	-1.23	-0.22	-0.62	-0.31	0.10	0.04
EPS Growth %	2.91%	-1.48%	-21.41%	0.72%	0.32%	0.82%	-1.82%	0.5%	1.32%	-0.63%
EPS (Basic)	0.61	-0.29	-6.50	-1.80	-1.23	-0.22	-0.62	-0.31	0.12	0.04
Diluted Shares Outstanding	94.92M	101.39M	13.11M	14.71M	14.84M	29.15M	44.14M	48.47M	82.42M	81.06M
Basic Shares Outstanding	94.92M	101.39M	13.11M	14.71M	14.84M	29.15M	44.14M	48.47M	67.51M	72.53M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	85.88M	71.87M	62.65M	52.98M	32.48M	55.72M	61.67M	44.88M	69.93M	60.08M
Cash & Short-Term Investments	76.37M	63.28M	51.16M	37.81M	17.79M	38.55M	38.98M	22.18M	44.56M	34.83M
Cash Only	76.37M	63.28M	51.16M	37.81M	17.79M	18.27M	38.98M	17.11M	23.63M	19.76M
Short-Term Investments	0	0	0	0	0	20.28M	0	5.07M	20.93M	15.07M
Accounts Receivable	0	693K	1.72M	4.73M	4.7M	2M	3.44M	4.59M	5.27M	2.91M
Days Sales Outstanding	-	27.5	29.8	50.41	31.37	11.61	32.76	35.14	29.38	19.88
Inventory	5.77M	5.25M	7.83M	8.57M	8.15M	13.08M	17.95M	16.8M	19.05M	21.24M
Days Inventory Outstanding	2.88K	227.96	187.71	336.24	273.21	439.15	400.83	313.06	302.47	318.83
Other Current Assets	3.33M	2.23M	1.5M	1.42M	1.52M	1.25M	380K	536K	611K	596K
Total Non-Current Assets+	11.37M	10.38M	9.56M	8.15M	12.91M	12.21M	12M	10.91M	14.5M	13.34M
Property, Plant & Equipment	9.74M	8.7M	7.68M	6.39M	10.95M	10.41M	9.92M	9.64M	10.88M	10.02M
Fixed Asset Turnover	0.45x	1.06x	2.75x	5.36x	4.99x	6.04x	3.87x	4.94x	6.02x	5.33x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	1.63M	1.68M	1.89M	1.76M	1.96M	1.8M	2.08M	1.27M	528K	462K
Total Assets+	97.25M	82.25M	72.21M	61.13M	45.39M	67.93M	73.67M	55.79M	84.43M	73.42M
Asset Turnover	0.04x	0.11x	0.29x	0.56x	1.20x	0.93x	0.52x	0.85x	0.78x	0.73x
Asset Growth %	0.24%	-0.15%	-0.12%	-0.15%	-0.26%	0.5%	0.08%	-0.24%	0.51%	-0.13%
Total Current Liabilities+	11.23M	66.21M	22.75M	25.35M	40.17M	86.47M	33.18M	32.43M	45.53M	25.62M
Accounts Payable	3.63M	4.01M	7.52M	5.21M	6.5M	7.22M	6.99M	5.86M	4.32M	4.53M
Days Payables Outstanding	1.81K	174.16	180.24	204.47	217.59	242.4	155.97	109.21	68.61	68.04
Short-Term Debt	0	53.87M	5.92M	0	4.3M	58.51M	0	0	21.66M	0
Deferred Revenue (Current)	504K	837K	1000K	1000K	1000K	1000K	1000K	1000K	0	0
Other Current Liabilities	5.98M	1.4M	526K	9.18M	1.75M	1.53M	1.51M	11.05M	4.94M	1.81M
Current Ratio	7.64x	1.09x	2.75x	2.09x	0.81x	0.64x	1.86x	1.38x	1.54x	2.34x
Quick Ratio	7.13x	1.01x	2.41x	1.75x	0.61x	0.49x	1.32x	0.87x	1.12x	1.52x
Cash Conversion Cycle	-	81.3	37.28	182.18	86.98	208.36	277.63	238.99	263.24	270.68
Total Non-Current Liabilities+	75.14M	25.99M	80.75M	88.66M	75.54M	8.5M	46.52M	34M	5.33M	4.58M
Long-Term Debt	72.1M	23.64M	46.27M	47.97M	50.96M	0	27.89M	28.19M	0	0
Capital Lease Obligations	0	0	0	0	4.53M	4.47M	4.38M	4.17M	4.62M	4.03M
Deferred Tax Liabilities	0	0	2.59M	2.37M	0	0	0	0	0	0
Other Non-Current Liabilities	2.3M	2.35M	7.64M	7.67M	3.07M	2.31M	2.47M	1.64M	714K	559K
Total Liabilities	86.38M	92.2M	103.51M	114.01M	115.71M	94.97M	79.7M	66.43M	50.87M	30.21M
Total Debt+	72.1M	77.52M	52.19M	47.97M	60.92M	64.4M	33.47M	33.47M	27.69M	5.53M
Net Debt	-4.28M	14.23M	1.02M	10.16M	43.13M	46.13M	-5.51M	16.36M	4.06M	-14.23M
Debt / Equity	6.63x	-	-	-	-	-	-	-	0.82x	0.13x
Debt / EBITDA	-	-	-	-	-	16.05x	-	-	2.38x	1.06x
Net Debt / EBITDA	-	-	-	-	-	11.50x	-	-	0.35x	-2.73x
Interest Coverage	-6.34x	-7.91x	-3.55x	-2.51x	-1.35x	0.28x	-2.72x	-5.15x	3.29x	3.69x
Total Equity+	10.87M	-9.96M	-31.29M	-52.88M	-70.32M	-27.04M	-6.04M	-10.64M	33.57M	43.21M
Equity Growth %	1.2%	-1.92%	-2.14%	-0.69%	-0.33%	0.62%	0.78%	-0.76%	4.15%	0.29%
Book Value per Share	0.11	-0.10	-2.39	-3.59	-4.74	-0.93	-0.14	-0.22	0.41	0.53
Total Shareholders' Equity	10.87M	-9.96M	-31.29M	-52.88M	-70.32M	-27.04M	-6.04M	-10.64M	33.57M	43.21M
Common Stock	100K	124K	144K	148K	15K	35K	46K	54K	73K	76K
Retained Earnings	-183.29M	-212.66M	-297.93M	-322.55M	-340.83M	-347.35M	-374.93M	-389.86M	-381.55M	-378.39M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-183.29M	-25.6M	-27.46M	-29.12M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-24.28M	-32.1M	-9.99M	-7.74M	-19.36M	-26.11M	-10.29M	-25M	-1.32M	8.67M
Operating CF Margin %	-5.56%	-3.49%	-0.47%	-0.23%	-0.35%	-0.42%	-0.27%	-0.52%	-0.02%	0.16%
Operating CF Growth %	0.17%	-0.32%	0.69%	0.23%	-1.5%	-0.35%	0.61%	-1.43%	0.95%	7.58%
Net Income	-27.28M	-29.18M	-85.28M	-26.46M	-18.28M	-6.52M	-27.58M	-14.93M	8.31M	2.93M
Depreciation & Amortization	2.37M	1.98M	1.92M	1.67M	1.62M	1.3M	1.12M	1.09M	1.19M	1.3M
Stock-Based Compensation	1.8M	988K	337K	514K	835K	3.13M	2.38M	2.08M	3.45M	3.25M
Deferred Taxes	1.56M	-7.59M	39.35M	-64K	-68K	0	0	0	-3.09M	236K
Other Non-Cash Items	569K	581K	4.57M	3.07M	3.37M	3.12M	3.9M	-1.23M	-638K	138K
Working Capital Changes	-3.3M	1.12M	29.1M	13.53M	-6.83M	-27.13M	9.9M	-12.02M	-10.54M	811K
Change in Receivables	523K	-1.13M	25K	-3.1M	188K	2.09M	-1.03M	-1.19M	-428K	2.32M
Change in Inventory	-2.32M	522K	-2.59M	-736K	414K	-4.93M	-4.87M	1.15M	-2.24M	-2.2M
Change in Payables	-1.87M	2.14M	4.9M	-520K	2.14M	0	0	0	0	0
Cash from Investing+	39.39M	-967K	-1.12M	-591K	-883K	-19.95M	18.92M	-5.04M	-16.71M	4.22M
Capital Expenditures	-464K	-849K	-971K	-686K	-627K	-655K	-1.46M	-628K	-1.15M	-1.28M
CapEx % of Revenue	0.11%	0.09%	0.05%	0.02%	0.01%	0.01%	0.04%	0.01%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	39.85M	-118K	-148K	95K	-256K	703K	380K	593K	-142K	83K
Cash from Financing+	6.63M	19.7M	-1.42M	-4.75M	0	46.47M	12.08M	8.24M	24.67M	-16.79M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	534K	14K	0	0	0	472K	0	2K	712K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-24.75M	-32.95M	-10.96M	-8.43M	-19.98M	-26.76M	-11.74M	-25.63M	-2.47M	7.39M
FCF Margin %	-5.67%	-3.58%	-0.52%	-0.25%	-0.37%	-0.43%	-0.31%	-0.54%	-0.04%	0.14%
FCF Growth %	0.18%	-0.33%	0.67%	0.23%	-1.37%	-0.34%	0.56%	-1.18%	0.9%	4%
FCF per Share	-0.26	-0.32	-0.84	-0.57	-1.35	-0.92	-0.27	-0.53	-0.03	0.09
FCF Conversion (FCF/Net Income)	-0.42x	1.09x	0.12x	0.29x	1.06x	4.00x	0.37x	1.67x	-0.16x	2.96x
Interest Paid	0	0	0	0	0	4.34M	3.41M	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	533.77%	-6411.57%	-	-	-	-	-	-	72.5%	7.64%
Return on Invested Capital (ROIC)	-	-457.46%	-	-	-	-	-406.69%	-170.55%	36.2%	8.82%
Gross Margin	83.27%	8.71%	27.74%	72.83%	80.08%	82.71%	57.37%	58.87%	64.91%	54.46%
Net Margin	1329.9%	-319.22%	-395.86%	-77.27%	-33.42%	-10.37%	-71.92%	-31.33%	12.69%	5.49%
Debt / Equity	6.63x	-	-	-	-	-	-	-	0.82x	0.13x
Interest Coverage	-6.34x	-7.91x	-3.55x	-2.51x	-1.35x	0.28x	-2.72x	-5.15x	3.29x	3.69x
FCF Conversion	-0.42x	1.09x	0.12x	0.29x	1.06x	4.00x	0.37x	1.67x	-0.16x	2.96x
Revenue Growth	-71.21%	110.79%	129.13%	62.44%	59.73%	15%	-39.03%	24.22%	37.48%	-18.47%

Revenue by Segment

	2018	2019	2021	2022	2023	2024
Product	5.32M	15.87M	-	-	-	52.98M
Product Growth	-	198.23%	-	-	-	-
License and Service	25.26M	-	-	-	-	418K
License and Service Growth	-	-	-	-	-	-
License and R&D Services	-	-	21.6M	22.35M	25.08M	-
License and R&D Services Growth	-	-	-	3.45%	12.22%	-
License And Service	-	38.83M	-	-	-	-
License And Service Growth	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Protalix BioTherapeutics, Inc. (PLX) has a price-to-earnings (P/E) ratio of 56.3x. This suggests investors expect higher future growth.

Growth & Financials

Protalix BioTherapeutics, Inc. (PLX) reported $61.8M in revenue for fiscal year 2024. This represents a 637% increase from $8.4M in 2011.

Protalix BioTherapeutics, Inc. (PLX) saw revenue decline by 18.5% over the past year.

Yes, Protalix BioTherapeutics, Inc. (PLX) is profitable, generating $5.4M in net income for fiscal year 2024 (5.5% net margin).

Dividend & Returns

Protalix BioTherapeutics, Inc. (PLX) has a return on equity (ROE) of 7.6%. This is below average, suggesting room for improvement.

Protalix BioTherapeutics, Inc. (PLX) had negative free cash flow of $11.7M in fiscal year 2024, likely due to heavy capital investments.